We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.65 | 1.50% | 44.10 | 45,224 | 14:22:49 |
1.
|
As Non-Executive Director of GSK, Dr Cox will receive standard annual fees of £85,000 per annum. To enhance the link between Non-Executive Directors and shareholders, at least 25% of her fees will be paid in the form of Ordinary Shares and allocated to a share account, and she will be able to invest part or all of the balance of her fees into the same share account.
|
2.
|
The Board has determined that Dr Cox will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Dr Cox’s appointment in accordance with Listing Rule 9.6.13R.
|
3.
|
With effect from 1 July 2016, the composition of the Board of GSK will be as follows:
|
Sir Philip Hampton
|
Non-Executive Chairman
|
Sir Andrew Witty
|
Chief Executive Officer
|
Mr Simon Dingemans
|
Chief Financial Officer
|
Dr Moncef Slaoui
|
Chairman, Global Vaccines
|
Professor Sir Roy Anderson
|
Independent Non-Executive Director
|
Mr Vindi Banga
|
Senior Independent Non-Executive Director
|
Ms Stacey Cartwright
Dr Vivienne Cox
|
Independent Non-Executive Director
Independent Non-Executive Director
|
Ms Lynn Elsenhans
Dr Jesse Goodman
|
Independent Non-Executive Director
Independent Non-Executive Director
|
Ms Judy Lewent
|
Independent Non-Executive Director
|
Mr Urs Rohner
|
Independent Non-Executive Director
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.
|
Registered in England & Wales:
No. 3888792
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions